PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 501–600 of 1,000
Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence
Dyhl-Polk, A., Kolmos, I. L., Kümler, I., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000093 · Cited by 43
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis
Raphael, J., Helou, J. A., Pritchard, K. I., & Naimark, D. M. J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.018 · Cited by 37
Huang, Z. L., Zhao, B., Qin, Z., Li, Y., Wang, T., Zhou, W., Zheng, J., Yang, S., Shi, Y., Fan, Y. L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.044 · Cited by 40
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
Targeting Signaling Pathways in Inflammatory Breast Cancer
Wang, X., Semba, T., Phi, L. T., Chainitikun, S., Iwase, T., Lim, B., & Ueno, N. T. (2020) · Cancers · doi:10.3390/cancers12092479 · Cited by 46
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer
Lim, J. S. J., Turner, N. C., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0563 · Cited by 39
Nagaraj, G., & Ma, C. X. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3316-4 · Cited by 40
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options
Rugo, H. S., Vidula, N., & Ma, C. X. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159198 · Cited by 51
Clinical development of CDK4/6 inhibitor for breast cancer
Iwata, H. (2018) · Breast Cancer · doi:10.1007/s12282-017-0827-3 · Cited by 39
Hsu, C.-L., Lui, K., Chi, L., Kuo, Y., Chao, Y., Yeh, C., Lee, L., Huang, Y., Lin, T., Huang, M.-Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0873-5 · Cited by 39
Zhang, C., Stockwell, S. R., Elbanna, M., Ketteler, R., Freeman, J., Al‐Lazikani, B., Eccles, S. A., Brandon, A. D. H., Raynaud, F. I., Hayes, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0850-2 · Cited by 40
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 44
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0432 · Cited by 40
Masuda, N., Nishimura, R., Takahashi, M., Inoue, K., Ohno, S., Iwata, H., Mori, Y., Hashigaki, S., Muramatsu, Y., Nagasawa, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13507 · Cited by 37
Watson, G. A., Deac, O. M., Aslam, R., O’Dwyer, R., Tierney, A., Sukor, S., & Kennedy, J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.002 · Cited by 38
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Basudan, A., Priedigkeit, N., Hartmaier, R. J., Sokol, E. S., Bahreini, A., Watters, R. J., Boisen, M. M., Bhargava, R., Weiss, K. R., Karsten, M. M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0946 · Cited by 40
Chao, D. T., Su, M., Tanlimco, S. G., Sho, M., Choi, D., Fox, M. D., Ye, S., Hsi, E. D., Durkin, L. M., Yin, J., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1332-x · Cited by 37
Changes in the mammary gland during aging and its links with breast diseases
Lin, J., Ye, S., Hao, K., Lin, L., Wu, X., Guo, M., Jiao, B., Chen, C., & Zhao, L. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023073 · Cited by 45
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Iglesias-Martinez, L. F., Kölch, W., & Santra, T. (2016) · Scientific Reports · doi:10.1038/srep37140 · Cited by 45
Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells
Shibata, M., Kanda, M., Tanaka, H., Umeda, S., Miwa, T., Shimizu, D., Hayashi, M., Inaishi, T., Miyajima, N., Adachi, Y., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5800 · Cited by 37
Temprine, K., Campbell, N. R., Huang, T. H., Langdon, E. M., Simon-Vermot, T., Mehta, K., Clapp, A., Chipman, M. E., & White, R. M. (2020) · Science Signaling · doi:10.1126/scisignal.aau1453 · Cited by 38
Ather, F., Hamidi, H., Fejzo, M. S., Letrent, S. P., Finn, R. S., Kabbinavar, F. F., Head, C. S., & Wong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056112 · Cited by 44
Tommasi, C., Airò, G., Pratticò, F., Testi, I., Corianò, M., Pellegrino, B., Denaro, N., Demurtas, L., Dessì, M., Murgia, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071873 · Cited by 47
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
Migliaccio, I., Leo, A. D., & Malorni, L. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000129 · Cited by 38
Recent advances in breast cancer research impacting clinical diagnostic practice
Reed, A. E. M., Croft, P. K., Kutasovic, J. R., Saunus, J. M., & Lakhani, S. R. (2019) · The Journal of Pathology · doi:10.1002/path.5199 · Cited by 37
Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
Sittithumcharee, G., Suppramote, O., Vaeteewoottacharn, K., Sirisuksakun, C., Jamnongsong, S., Laphanuwat, P., Suntiparpluacha, M., Matha, A., Chusorn, P., Buraphat, P., et al. (2019) · Hepatology · doi:10.1002/hep.30704 · Cited by 39
Digiacomo, G., Fumarola, C., Monica, S. L., Bonelli, M. A., Cretella, D., Alfieri, R. R., Cavazzoni, A., Galetti, M., Bertolini, P., Missale, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.563249 · Cited by 41
Janoštiak, R., Torres-Sanchez, A., Posas, F., & de Nadal, E. (2022) · Cancers · doi:10.3390/cancers14051265 · Cited by 42
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Yu, Z., He, S., Wang, D., Patel, H., Miller, C. P., Brown, J. L., Hattersley, G., & Saeh, J. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0670 · Cited by 47
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, H., Huang, D., Yang, F., & Guan, X. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4612-y · Cited by 36
Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway
Wang, J., Yang, T., Chen, H., Li, H., & Zheng, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.167 · Cited by 34
Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, D., Volovăț, S. R., & Cardoso, F. (2018) · The Breast · doi:10.1016/j.breast.2018.10.001 · Cited by 40
Elmi, A., Makvandi, M., Weng, C.-C., Hou, C., Clark, A. S., Mach, R. H., & Mankoff, D. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2769 · Cited by 34
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
Clifton, K., Yi, M., Kimmel, J., Litton, J. K., Tripathy, D., & Karuturi, M. S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05181-4 · Cited by 36
Sun, Y., Sun, Y., Yan, K. H., Li, Z., Xu, C., Geng, Y., Pan, C., Chen, X., Zhang, L., & Xi, Q. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.043 · Cited by 39
Yang, B., Sun, L., & Liang, L. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0576-3 · Cited by 35
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
Palleschi, M., Maltoni, R., Ravaioli, S., Vagheggini, A., Mannozzi, F., Fanini, F., Pirini, F., Tumedei, M. M., Barzotti, E., Cecconetto, L., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10080573 · Cited by 36
Spring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 36
Updates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 40
Pesch, A. M., Hirsh, N. H., Michmerhuizen, A. R., Jungles, K. M., Wilder-Romans, K., Chandler, B. C., Liu, M., Lerner, L. M., Nino, C. A., Ward, C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154402 · Cited by 39
Viganò, L., Locatelli, A., Ulisse, A., Galbardi, B., Dugo, M., Tosi, D., Tacchetti, C., Daniele, T., Győrffy, B., Sica, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3185 · Cited by 45
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 39
Knudsen, E. S., Schultz, E., Hamilton, D., Attwood, K. M., Edge, S. B., O’Connor, T. L., Levine, E. G., & Witkiewicz, A. K. (2022) · The Oncologist · doi:10.1093/oncolo/oyac089 · Cited by 35
Kamdje, A. H. N., Etet, P. F. S., Vecchio, L., Tagne, R. S., Amvene, J. M., Muller, J.-M., Krampera, M., & Lukong, K. E. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.769 · Cited by 41
Modeling and Targeting MYC Genes in Childhood Brain Tumors
Hutter, S., Bolin, S., Weishaupt, H., & Swartling, F. J. (2017) · Genes · doi:10.3390/genes8040107 · Cited by 39
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 39
The novel role of miRNAs for tamoxifen resistance in human breast cancer
Zhang, W., Xu, J., Shi, Y., Sun, Q., Zhang, Q., & Guan, X. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1887-1 · Cited by 36
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
Schröder, L. B. W., & McDonald, K. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00259 · Cited by 41
Narayan, V., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., O'Dwyer, P. J., & Vaughn, D. J. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.010 · Cited by 35
Fejzo, M. S., Anderson, L. A., Chen, H., Guandique, E., Kalous, O., Conklin, D. F., & Slamon, D. J. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22459 · Cited by 33
du Rusquec, P., Palpacuer, C., Campion, L., Patsouris, A., Augereau, P., Gourmelon, C., Robert, M., Dumas, L. E., Folliard, C., Campone, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4623-8 · Cited by 33
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
Rugo, H. S., Cristofanilli, M., Loibl, S., Harbeck, N., DeMichele, A. M., Iwata, H., Park, Y. H., Brufsky, A., Theall, K. P., Huang, X., et al. (2021) · The Oncologist · doi:10.1002/onco.13833 · Cited by 33
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 42
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Giannone, G., Tuninetti, V., Ghisoni, E., Genta, S., Scotto, G., Mittica, G., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092353 · Cited by 35
McCain, J. (2015) · PubMed · Cited by 42
Li, Y., Li, S., Chen, J., Shao, T., Jiang, C., Wang, Y., Chen, H., Xu, J., & Li, X. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu256 · Cited by 34
Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers
Mikhail, S., Albanese, C., & Pishvaian, M. J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.01.008 · Cited by 36
Tumor Suppressors Status in Cancer Cell Line Encyclopedia
Sonkin, D., Hassan, M., Murphy, D. J., & Tatarinova, T. V. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.04.001 · Cited by 33
O'Sullivan, C. C. (2015) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/2/4/1029 · Cited by 35
CDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
Jusino, S., Fernández-Padín, F. M., & Saavedra, H. I. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.24 · Cited by 35
Sante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 34
The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer
Iida, M., Nakamura, M., Tokuda, E., Toyosawa, D., Niwa, T., Ohuchi, N., Ishida, T., & Hayashi, S. (2019) · Oncotarget · doi:10.18632/oncotarget.27127 · Cited by 35
Rugo, H. S., Finn, R. S., Gelmon, K. A., Joy, A. A., Harbeck, N., Castrellon, A. B., Mukai, H., Walshe, J. M., Mori, A., Gauthier, E., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.009 · Cited by 34
Jo, H., Park, Y., Kim, T., Kim, J., Lee, J. S., Kim, S. Y., Chung, J.-I., Ko, H. Y., Pyun, J., Kim, K. S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06822-4 · Cited by 34
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
Li, J., Wang, Z., & Shao, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2095 · Cited by 31
Teh, J. L. F., Purwin, T. J., Greenawalt, E. J., Chervoneva, I., Goldberg, A. F., Davies, M. A., & Aplin, A. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3384 · Cited by 36
Nomanbhoy, T. K., Sharma, G., Brown, H., Wu, J., Aban, A., Vogeti, S., Alemayehu, S., Sykes, M., Rosenblum, J. S., & Kozarich, J. W. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00629 · Cited by 31
Cell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Metastasis inhibition in breast cancer by targeting cancer cell extravasation
Cominetti, M. R., Altei, W. F., & Selistre-de-Araújo, H. S. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s166725 · Cited by 38
Ratoša, I., Oražem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., Cerbai, C., Desideri, I., Ribnikar, D., Marinko, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.05.013 · Cited by 31
Finn, R. S., Cristofanilli, M., Ettl, J., Gelmon, K. A., Colleoni, M. A., Giorgetti, C., Gauthier, E. R., Liu, Y., Lu, D. R., Zhang, Z., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05782-4 · Cited by 33
Management of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 36
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhu, Z., Turner, N. C., Loi, S., André, F., Martín, M., Dieras, V. C., Gelmon, K. A., Harbeck, N., Zhang, C., Cao, J. Q., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00297-1 · Cited by 41
Lee, J. S., Hackbart, H., Cui, X., & Yuan, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411791 · Cited by 37
CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard
Wolff, A. C. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611926 · Cited by 34
Yi, Y., Lan, X., Li, Y., Yan, C., Lv, J., Zhang, T., & Jiang, W. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.005 · Cited by 35
Recent Progress in CDK4/6 Inhibitors and PROTACs
Wang, H., Ba, J., Kang, Y., Gong, Z., Liang, T., Zhang, Y., Qi, J., & Wang, J. (2023) · Molecules · doi:10.3390/molecules28248060 · Cited by 33
Ladd, B., Mazzola, A. M., Bihani, T., Lai, Z., Bradford, J. R., Collins, M. P., Barry, E., Goeppert, A. U., Weir, H. M., Hearne, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10852 · Cited by 32
Glück, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.08.004 · Cited by 33
Rossi, L., Biagioni, C., McCartney, A., Migliaccio, I., Curigliano, G., Sanna, G., Moretti, E., Minisini, A. M., Cinieri, S., Tondini, C. A., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1149-5 · Cited by 31
Jang, H.-J., Truong, C., Lo, E. M., Holmes, H. M., Ramos, D., Ramineni, M., Lee, J., Wang, D. Y., Pietropaolo, M., Ripley, R. T., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.08.054 · Cited by 33
Junk, D. J., Cipriano, R., Stampfer, M. R., & Jackson, M. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053776 · Cited by 30
Li, C., Qi, L., Bellail, A. C., Hao, C., & Liu, T. (2014) · Oncology Letters · doi:10.3892/ol.2014.1957 · Cited by 33
Lipid metabolism involved in progression and drug resistance of breast cancer
Fu, W., Sun, A., & Dai, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101376 · Cited by 35
Knudsen, E. S., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11588 · Cited by 32
Preclinical and clinical development of palbociclib and future perspectives
de Dueñas, E. M., Gavilá-Gregori, J., Olmos-Antón, S., Santaballa, A., Lluch-Hernández, A., Domínguez, E. E., Rivero-Silva, M., & Llombart‐Cussac, A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1850-3 · Cited by 36
CDK4-6 inhibitors in breast cancer: current status and future development
Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 32
Estrogen receptor beta expression correlates with proliferation in desmoid tumors
Santti, K., Ihalainen, H., Rönty, M. J., Karlsson, C., Haglund, C. H., Sampo, M. M., Tarkkanen, M., & BLOMQVIST, C. P. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25407 · Cited by 34
Sarhan, M. O., El‐Karim, S. S. A., Anwar, M. M., Gouda, R. H., Zaghary, W. A., & Khedr, M. A. (2021) · Molecules · doi:10.3390/molecules26082273 · Cited by 33
Fallah, Y., Demas, D. M., Lu, J., He, W., & Shajahan‐Haq, A. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681530 · Cited by 29
Badri, S. E., Tahir, B., Balachandran, K., Bezecny, P., Britton, F., Davies, D. M., DeSouza, K., Dixon, S., Hills, D., Moe, M., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.10.010 · Cited by 30
Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 32
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.